ACRS - Dosing underway for Aclaris's ATI-1777 in mid-stage atopic dermatitis study

Aclaris Therapeutics (ACRS) has dosed the first patient in its Phase 2a trial evaluating ATI-1777 for the treatment of moderate to severe atopic dermatitis.ATI-1777 is an investigational topical “soft” Janus kinase 1/3 inhibitor, and was developed internally utilizing Aclaris’ proprietary KINect drug discovery platform.The 42-subject trial will determine the efficacy, safety, tolerability and pharmacokinetics of ATI-1777, and subjects will apply ATI-1777 or vehicle twice daily for 28 days. The primary endpoint is the percentage change from baseline in the Eczema Area and Severity Index score at week 4.

For further details see:

Dosing underway for Aclaris's ATI-1777 in mid-stage atopic dermatitis study